Kim Kardashian Confirms Her "Lifer" Friend Lindsay May Died After Cancer Battle Kim Kardashian mourned the death of Lindsay May, a member of her "lifers" group of childhood friends: "I felt this ...

Updated results from a Phase 1/2a trial show safety and efficacy of [212Pb]VMT-α-NET in treating neuroendocrine tumors.

After Tyler Henry underwent surgery to remove a brain tumor, the celebrity medium shared an update on his health journey.

Please provide your email address to receive an email when new articles are posted on . An AACE consensus statement outlines treatment recommendations for MEN1-associated tumors and genetic ...

New cell therapy shows promising results in advanced tumor diseases Research success at Dresden University Hospital around Martin Wermke Date: April 25, 2025 Source: Technische Universität ...

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment with a combination of immunotherapy and what has been described in a news ...

Dr. Aman Chauhan, leader of the Neuroendocrine Tumor Program at Sylvester Comprehensive Cancer Center, is leading a clinical trial testing a combination of immunotherapy drugs and a tumor-busting ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

655Background: Pancreatic neuroendocrine tumors (PNETs) have varying biologic behavior based on factors including tumor grade. Many prognostic factors can only be determined post-pancreatectomy; thus, ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients with gastroenteropancreatic neuroendocrine tumors, a phase 3 trial found.